With the end of August, the current 2022 semi-annual performance reports of major pharmaceutical companies have also been released
.
According to incomplete statistics, as of August 25, a total of 106 pharmaceutical companies in A shares disclosed their financial reports for the first half of 2022, and more than 60% of pharmaceutical companies achieved both
operating income and net profit.
In this regard, the industry believes that the pharmaceutical industry will maintain a high-prosperity development trend for a long time, and related enterprises will continue to usher in positive.
It is worth noting that under the overall development of the industry, there are several major high-growth sectors worthy of attention
.
The pharmaceutical industry will maintain a high boom development trend for a long time (Source: Pharmaceutical Network)
Innovative medicine
Innovative medicine
Innovation is the general trend
of transformation and upgrading of pharmaceutical companies.
Under the background of accelerating the approval and review of new drugs, the release of favorable policies, the enthusiasm for pharmaceutical investment, and the overall environment of pharmaceutical innovation, China's innovative drug research and development is showing a strong growth momentum, the number of entrants is increasing, and the innovative results are constantly emerging
.
Statistics show that from 2012 to 2021, the number of listed companies developing innovative drugs in China increased from 4 to 116
.
According to the incomplete statistics of the State Food and Drug Administration, a total of 49 new drugs were listed in 2020, and the number of new drugs approved in China reached 20, which is getting closer
than the number of imported new drugs.
It is worth mentioning that in addition to the accelerated emergence of innovative achievements, innovation is also constantly bringing new market increments
to domestic pharmaceutical companies.
For example, on August 26, Hansen Pharmaceutical released a semi-annual performance report showing that the company achieved revenue of about 4.
434 billion yuan in the first half of the year, of which the revenue of innovative drugs was about 2.
321 billion yuan, an increase of about 84.
8% year-on-year, and the proportion of innovative drugs in revenue rose from about 28.
5% in the same period of 2021 to about 52.
3%, setting a new high
.
In addition, China's biopharmaceutical semi-annual report also disclosed that the company's innovative drug revenue will account for 24% of this year, and the revenue of innovative drugs in 2023 is expected to exceed the mark
of 10 billion yuan.
From the above point of view, the industry generally believes that innovative drugs will still be the golden track
in the pharmaceutical sector.
Driven by domestic demand, investment in innovative drugs will continue to be a major trend
.
Medical devices
Medical devices
Although in recent years, medical insurance control fees and collection and price reductions have brought some concerns and market pressure
to innovative medical devices.
But at the same time, domestic medical devices are also ushering in more favorable policies
.
For example, on August 19, a video conference of responsible comrades of the national departments in charge of industry and information technology was held
in Beijing.
Among them, the meeting stressed that it is necessary to increase the development of emerging industries, formulate and introduce policies to promote the innovation and development of energy electronics, high-end medical devices and other industries, and accelerate the development and growth
of big data, cloud computing, artificial intelligence, robotics, green environmental protection and other industries.
On July 13, the Beijing Municipal Medical Insurance Bureau issued the Notice on Printing and Distributing the Administrative Measures for the Payment of CHS-DRG Paid New Drugs Except new technologies (for trial implementation), which clarifies that innovative drugs, innovative medical devices, and innovative medical service projects can be paid separately without DRG
With the continuous release of policies to support domestic industries, it means that in the future, China's policy orientation and policy trends for innovative medical devices will be clearer, which will help accelerate the pace of domestic substitution and release greater penetration space
.
In this regard, the industry believes that the prospect of innovative medical devices can be expected, optimistic about domestic medical device enterprises with research and development capabilities and manufacturing capabilities, these enterprises may accelerate the breakthrough of imported technology monopolies
in the future or in some fields.
CXO
CXO
Judging from the performance of CXO companies that released semi-annual reports, the net profit attributable to the mother of WuXi AppTec, Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, Yaokang Biologics and other companies has exceeded 50%
year-on-year growth.
Among them, the net profit attributable to Boteng shares and Gloria Ying increased by more than 300%
year-on-year.
Specifically, In the first half of this year, Kai Lai Ying achieved revenue of RMB5.
034 billion (the same unit below), an increase of 186.
7% year-on-year; Net profit attributable to shareholders of listed companies was 1.
74 billion yuan, an increase of 305.
3% year-on-year; The adjusted net profit attributable to shareholders of listed companies was 1.
537 billion yuan, an increase of 244.
8%
year-on-year.
In the first half of the year, Boteng's operating income increased by 211.
67% year-on-year to 3.
914 billion yuan; net profit attributable to shareholders of listed companies increased by 465.
01% year-on-year to 1.
212 billion yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses increased by 501.
87% year-on-year to 1.
211 billion yuan
.
For the performance of CXO companies soared, the industry believes that the main reason is that the CXO industry has benefited from the continuous introduction of a series of policies in recent years, and the attitude of vigorously supporting the rapid development of the innovative pharmaceutical and device industry is clear, pharmaceutical innovation is the main logic of the current development of the entire industry, in this context, the CXO industry is expected to benefit for a long time, and related enterprises will also usher in more benefits
.
In this context, it is suggested that we can focus on the clinical CRO leaders
who benefit from the domestic innovative drug boom.
